Single daily dose of aminoglycosides in the treatment of continuous ambulatory peritoneal dialysis peritonitis

• Published in: Peritoneal dialysis international Vol. 13; no. 2_suppl; pp. S355 - S356
• Main Author: VAS, S. I
• Format: Conference Proceeding Journal Article
• Language: English
• Published: Milton, ON Multimed 1993
• Subjects: Administration, Oral; Aminoglycosides; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - pharmacokinetics; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Biological and medical sciences; Drug Administration Schedule; Humans; Medical sciences; Peritoneal Dialysis, Continuous Ambulatory - adverse effects; Peritonitis - drug therapy; Peritonitis - etiology; Pharmacology. Drug treatments; Human; Urinary system disease; Continuous; Administration schedule; Peritoneal dialysis; Infection; Extrarenal dialysis; Antibiotic; Chemotherapy; Treatment; Abdominal disease; Aminoglycoside; Renal failure; Bacteriosis; Complication; Single daily dose; Ambulatory; Antibacterial agent; Peritonitis
• ISSN: 0896-8608; 1718-4304
• DOI: 10.1177/089686089301302s89

Toxicity of aminoglycosides is a major concern in the treatment of continuous ambulatory peritoneal dialysis (CAPD) peritonitis. The relatively high blood levels and prolonged and repeated usage may all be contributory. The recognition of the so-called postantibiotic effect, together with the increased phagocytosis of antibiotic-treated cells, may introduce a new mode of therapy with once-daily dosage. Intermittent therapy with vancomycin is already generally accepted. The extension of this modality to antibiotic therapy is discussed.